Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
Information source: Hanmi Pharmaceutical Company Limited
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Kidney Disease; Hyperlipidemia
Intervention: Simvast CR (Drug); Zocor (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Hanmi Pharmaceutical Company Limited Official(s) and/or principal investigator(s): Kyung-mi Park, Ph.D, Study Director, Affiliation: Hanmi Pharmaceutical Company Limited ( e-mail: kmpark@hanmi.co.kr )
Summary
Study design
- Multicenter, double-dummy, double-blinded, randomized, Phase 4 study
- Patients will be randomized to either a study group or a control group in a 1: 1 ratio,
and will be orally administered the assigned drugs
Study Objective
- The study is designed to demonstrate that efficacy and safety of morning dosing of Simvast
Controlled Release (CR) Tab is not inferior to evening dosing of Zocor Tab in patients with
stage 3,4,5 chronic kidney disease with hyperlipidemia
Primary objective
- to assess the percent change of LDL-C at Week 8 from baseline in Chronic Kidney
Disease(CKD) stage 3,4,5 with hyperlipidemia subjects.
Clinical Details
Official title: Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Percent change of LDL-C
Secondary outcome: Change and percent change of TC, HDL-C, TGAccomplishment rate of therapeutic goals
Detailed description:
The secondary objectives of the study are as follows:
- to assess the change and percent change of TC, HDL-C, TG from baseline.
- to assess the accomplishment rate of therapeutic goals based on the therapeutic
guidance for hyperlipidemia of the Korean Society of Lipidology and Atherosclerosis.
Eligibility
Minimum age: 20 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Patient with age of 20 to 75 (inclusive)
- Patients with fasting serum lipid panels meeting the followings:
- At Visit 1 screening 100mg/dL ≤ LDL-C < 220 mg/dL Triglyceride < 400mg/dL
However, if the patient has been treated with antihyperlipidemics for 4
consecutive weeks or longer at the time of screening, it should be 100mg/ dL ≤
LDL-C < 160 mg/dL.
- At Visit 2 screening 100mg/dL ≤ LDL-C < 220 mg/dL Triglyceride < 400mg/dL
- Patients with CKD stage 3 to 5.
- Subjects considered requiring medication by the principal investigator based on the
therapeutic - guidance for hyperlipidemia of the Korean Society of Lipidology and
Atherosclerosis.
- Patients who understand the study procedures and signed the informed consent form.
Exclusion criteria:
- Patients with a hypersensitivity to HMG-CoA reductase inhibitor or any of its
ingredients.
- Patients who consume more than 14 units of alcohol a week, who are considered to have
a history of drug overdose within 12 months of screening by the investigator, or who
abuse other drugs.
- Patients with the following history:
- Active gallbladder disease within 12 months of screening (patients who had
cholecystectomy are eligible for the study).
- Pancreatitis or liver disease (AST or ALT > 2 times the upper limit of the
normal range at Visits 1 and 2).
- Patients with uncontrolled diabetes mellitus (HbA1c ≥ 9. 0 %).
- Patients with hypotension (systolic blood pressure< 90mmHg or diastolic blood
pressure<50mmHg).
- Patients with uncontrolled hypertension: mean systolic blood pressure (SBP)>
160mmHg or mean diastolic blood pressure (DBP) > 100mmHg at Visit 2.
- Patients with myocardial infarction or who had coronary artery bypass or
angioplasty within 6 months before screening.
- Patients who had stroke, transient ischemic attack (TIA), or deep vein
thrombosis (DVT) within 6 months of screening.
- Patients who had been treated for carotid artery disease, peripheral artery
disease, or abdominal aortic aneurysm.
- Patients with serious heart disease (patients with NYHA class (Attachment 4) III
or IV congestive heart failure, unstable angina pectoris, or acute myocardial
infarction).
- Patients who were diagnosed with malignancy within 5 years or who have active
tumors.
- Patients with fibromyalgia, myopathy, rhadomyolysis, or sudden muscle pain, or
patients who experienced adverse events during the previous treatment with
statins.
- Patients with mental illnesses considered by the investigator serious enough to
adversely affect the patients' participation in the study.
- Patients with uncontrolled primary hypothyroidism.
- Patients with active peptic ulcer disease.
- Patients with gastrointestinal conditions that may restrict drug absorptions,
such as chronic diarrhea, inflammatory colic disease, partial ileal bypass,
gastrorrhaphy, or gastric banding.
- Screening CPK level > 3 times the upper limit of the normal range.
- Patients on immunosuppressives after kidney transplantation.
- Patients who need to be on immunosuppressives for other reasons.
- Patients who have participated in another clinical trial within the last 4 weeks of
screening (except those who participated in clinical trials including observational
studies that do not involve interventions such as medication).
- Pregnant women, lactating women, or women of childbearing potential who do not use
appropriate contraceptives.
- Patients currently on dialysis.
- Other patients considered ineligible by the principal investigator and investigators.
Locations and Contacts
Gachon University Gil Hospital, Incheon, Korea, Republic of
Eulji General Hospital, Seoul, Korea, Republic of
Hanyang University Seoul Hospital, Seoul, Korea, Republic of
Korea University Anam Hospital, Seoul, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
Hallym University Medical Center, Anyang-si, Gyeonggi-do, Korea, Republic of
Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
Additional Information
Starting date: December 2010
Last updated: March 26, 2012
|